Designing novel protein therapeutics and identifying appropriate targets - WHITEPAPER
Since the introduction around 30 years ago of the first recombinant protein therapeutic (human insulin), protein therapies have increased dramatically in number and frequency of usage. The benefits of proteins over small-molecule drugs rooted their extensive influence in the pharmaceutical market and there are currently more than 130 different proteins or peptides approved for clinical use by the FDA, and many more are in development.
This whitepaper explores designing novel protein therapeutics and identifying appropriate targets, including:
- The challenges with creating novel protein therapeutics in the R&D stage and how can they be overcome
- Factors to consider when identifying targets and how does it affect protein design
- Best ways to identify appropriate targets
- Understanding Bioavailability
To download the exclusive whitepaper simply log in or register for a KNect365 account, which will give you access to all our exclusive premium content.
Have any questions about the report or interested in sponsoring a future whitepaper? Email email@example.com.
ABOUT THE AUTHOR: Dr Catarina Carrao gained a PhD in Biochemistry from Northeastern Ohio Medical and Pharmacy University and an M.Phil in Biochemistry at the University of Beira Interior. She has worked as a researcher at Max F. Perutz Laboratories, Yale Cardiovascular Center at Yale University School of Medicine, and the Center Cardiovascular Research (CCR) at Charité Medical University.